events welcomeprint share catalyst pharmaceuticals inc. catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases . catalyst is currently developing amifampridine phosphate with the proposed tradename of firdapse for the treatment of lambert eaton myasthenic syndrome lems . lems is a rare autoimmune neuromuscular disorder in which the body attacks and interferes with the communication between nerve and muscle cells primarily causing progressively severe muscle weakness and fatigue . catalyst has completed a 38 subject pivotal phase iii global multi centered clinical trial and showed amifampridine phosphate to be safe and effective in the treatment of patients with lems . expanded access program catalyst pharmaceuticals has announced the initiation of an expanded access program eap for amifampridine phosphate which is a phase iv open label study where patients who are diagnosed with lems or certain types of congenital myasthenic syndromes cms and meet the inclusion and exclusion criteria can receive amifampridine phosphate at no cost when a patient s physician feels this investigational medication can help improve his or her condition . 1 844 347 3277 read more pipeline catalyst pharmaceuticals is also studying amifampridine phosphate in other neurological orphan indications including congenital myasthenic syndromes cms and downbeat nystagmus . other pipeline programs include cpp 115 which is under investigation in several neurological conditions such as post traumatic stress disorders tourette s disorders and infantile spasms . read more patient advocacy some of the numerous advocacy organizations which catalyst is working with to help people with rare diseases include dysautonomia internationalwww.dysautonomiainternational.org national organization for rare disorders nord www.rarediseases.org global geneswww.globalgenes.orgwww.livingwithlems.org muscular dystrophy associationwww.mda.org what s new oct. 13 2016 catalyst pharmaceuticals to present at 15th annual bio investor forum read more sept. 19 2016 catalyst pharmaceuticals announces publication of cpp 115 clinical efficacy data for infantile spasms in epilepsy & behavior case reports read more sept. 14 2016 catalyst pharmaceuticals announces launch of expanded access program website and participation at the american association of neuromuscular & electrodiagnostic medicine conference read more sept. 02 2016 catalyst pharmaceuticals announces fda orphan drug designation of firdapse for the treatment of myasthenia gravis read more aug. 09 2016 catalyst pharmaceuticals announces second quarter 2016 financial results and provides product development update read more aug. 01 2016 catalyst pharmaceuticals to hold second quarter financial results and corporate update conference call and webcast on wednesday august 10th 2016 read more june 13 2016 catalyst pharmaceuticals announces agreement with fda on confirmatory phase 3 study protocol for firdapse in lambert eaton myasthenic syndrome read more june 01 2016 catalyst pharmaceuticals to present at the jefferies 2016 healthcare conference read more may 18 2016 catalyst pharmaceutical s firdapse phase 3 study published in muscle & nerve read more may 17 2016 catalyst pharmaceuticals announces reduction in workforce as part of operating expense management plan read more may 10 2016 catalyst pharmaceuticals announces first quarter 2016 financial results and provides corporate update read more catalystpharma privacy policy site map webmail login website by axxiem